应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AMGN 安进
未开盘 04-10 16:00:00 EDT
281.41
-9.68
-3.33%
盘后
282.50
+1.09
+0.39%
19:55 EDT
最高
288.52
最低
269.67
成交量
467.91万
今开
287.98
昨收
291.09
日振幅
6.48%
总市值
1,513亿
流通市值
1,509亿
总股本
5.38亿
成交额
13.06亿
换手率
0.87%
流通股本
5.36亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
安进盘中异动 股价大涨3.03%报334.69美元
市场透视 · 03-10
安进盘中异动 股价大涨3.03%报334.69美元
【安进：Rocatinlimab治疗中重度特应性皮炎研究达到共同主要终点】 3月8日，安进公司与协和麒麟株式会社公布了ROCKET III期临床试验项目的最新结果。该项目正在评估rocatinlimab用于治疗中重度特应性皮炎的疗效。IGNITE研究评估了rocatinlimab的两种剂量强度，达到了共同主要终点和所有关键次要终点，两种剂量组相较于安慰剂组均显示出统计学显著差异。
金融界 · 03-08
【安进：Rocatinlimab治疗中重度特应性皮炎研究达到共同主要终点】 3月8日，安进公司与协和麒麟株式会社公布了ROCKET III期临床试验项目的最新结果。该项目正在评估rocatinlimab用于治疗中重度特应性皮炎的疗效。IGNITE研究评估了rocatinlimab的两种剂量强度，达到了共同主要终点和所有关键次要终点，两种剂量组相较于安慰剂组均显示出统计学显著差异。
医药生物行业专题：海外制药企业2024Q4&全年业绩回顾
国信证券股份有... · 03-07
医药生物行业专题：海外制药企业2024Q4&全年业绩回顾
安进(AMGN.US)AMG 133启动减重III期临床
智通财经 · 03-07
安进(AMGN.US)AMG 133启动减重III期临床
首个肿瘤mRNA疫苗有望在2027年推出；安进减肥药启动III期临床
Ofweek光电信息网 · 03-07
首个肿瘤mRNA疫苗有望在2027年推出；安进减肥药启动III期临床
每月1针！安进AMG 133启动减重III期临床
医药魔方 · 03-06
每月1针！安进AMG 133启动减重III期临床
美银证券分析师：强生等五支生物制药股可能会蓄势突破
老虎资讯综合 · 03-06
美银证券分析师：强生等五支生物制药股可能会蓄势突破
B of A Securities：维持Amgen(AMGN.US)评级，由低于大市调整至低于大市评级, 目标价由275.00美元调整至294.00美元。
金融界 · 03-05
B of A Securities：维持Amgen(AMGN.US)评级，由低于大市调整至低于大市评级, 目标价由275.00美元调整至294.00美元。
百济神州，正在走安进曾经的路
医曜 · 02-27
百济神州，正在走安进曾经的路
安进盘中异动 股价大跌3.00%报306.15美元
市场透视 · 02-26
安进盘中异动 股价大跌3.00%报306.15美元
生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道
智通财经 · 02-24
生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道
安进承诺今年将在印度新技术中心投资约2亿美元
格隆汇 · 02-24
安进承诺今年将在印度新技术中心投资约2亿美元
华泰证券：国产GLP-1产品有望抢占全球市场份额
财中社 · 02-24
华泰证券：国产GLP-1产品有望抢占全球市场份额
安进涨0.69% 股价突破300美元大关
市场透视 · 02-21
安进涨0.69% 股价突破300美元大关
中银证券安进债券A连续7个交易日下跌，区间累计跌幅2.52%
金融界 · 02-18
中银证券安进债券A连续7个交易日下跌，区间累计跌幅2.52%
从被狙击到反击，中国Biotech正面硬刚跨国药企
健识局 · 02-18
从被狙击到反击，中国Biotech正面硬刚跨国药企
安进下跌1.23%，报290.98美元/股
金融界 · 02-14
安进下跌1.23%，报290.98美元/股
安进下跌1.21%，报294.183美元/股
金融界 · 02-07
安进下跌1.21%，报294.183美元/股
一药企宣布，暂停开发减肥药
康可药研 · 02-07
一药企宣布，暂停开发减肥药
加载更多
公司概况
公司名称：
安进
所属市场：
NASDAQ
上市日期：
--
主营业务：
Amgen Inc是一家生物技术公司。该公司从事发现、开发、生产和提供治疗最棘手疾病的药物。该公司专注于医疗需求尚未得到满足的领域，并利用专业知识努力寻求改善人们生活的解决方案。该公司在人类治疗领域开展业务。该公司的营销产品组合包括EPOGEN（阿法依泊汀）、Aranesp（阿法达贝泊汀）、Parsabiv（etelcalcetide）、Neulasta（培非格司亭）；KANJINTI（曲妥珠单抗）、Otezla、BLINCYTO（blinatumomab）、ACTIMMUNE（干扰素γ-1b）、Neulasta（培非格司亭）、Sensipar/Mimpara（西那卡塞）、Prolia（地舒单抗）、ENBREL、QUINSAIR（左氧氟沙星）、Repatha（依洛尤单抗）等。该公司在美国和加拿大销售肿瘤坏死因子阻断剂ENBREL。该公司在全球许多国家销售抑制磷酸二酯酶4的小分子药物Otezla。该公司在全球许多国家销售前蛋白转化酶枯草溶菌素/kexin 9型 (PCSK9) 抑制剂Repatha。
发行价格：
--
{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":281.41,"timestamp":1744315200000,"preClose":291.09,"halted":0,"volume":4679096,"hourTrading":{"tag":"盘后","latestPrice":282.5,"preClose":281.41,"latestTime":"19:55 EDT","volume":142815,"amount":40190628.2266,"timestamp":1744329326245},"delay":0,"floatShares":536123158,"shares":537650624,"eps":7.56,"marketStatus":"未开盘","change":-9.68,"latestTime":"04-10 16:00:00 EDT","open":287.98,"high":288.5225,"low":269.67,"amount":1306402199.4712,"amplitude":0.064765,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.56,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1744358400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":291.09,"dividendRate":0.031982,"preHourTrading":{"tag":"盘前","latestPrice":287.39,"preClose":291.09,"latestTime":"09:29 EDT","volume":7900,"amount":2282625.7630000003,"timestamp":1744291766074},"postHourTrading":{"tag":"盘后","latestPrice":282.5,"preClose":281.41,"latestTime":"19:55 EDT","volume":142815,"amount":40190628.2266,"timestamp":1744329326245},"volumeRatio":0.990933,"impliedVol":0.5057,"impliedVolPercentile":0.956},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2518276906","title":"安进盘中异动 股价大涨3.03%报334.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276906","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518276906?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:12","pubTimestamp":1741615977,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时12分，安进股票出现波动，股价大幅拉升3.03%。截至发稿，该股报334.69美元/股，成交量58.2511万股，换手率0.11%，振幅3.63%。最近的财报数据显示，该股实现营业收入332.32亿美元，净利润40.90亿美元，每股收益7.62美元，毛利213.33亿美元，市盈率44.26倍。安进股票所在的制药行业中，整体跌幅为1.58%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022125896404054&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022125896404054&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","SG9999001440.SGD","LU0122379950.USD","LU1571399168.USD","BK4581","BK4534","LU0289739699.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4588","BK4599","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU2242652126.USD","BK4533","IE00BFTCPJ56.SGD","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","LU0868494617.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2517442358","title":"【安进：Rocatinlimab治疗中重度特应性皮炎研究达到共同主要终点】 3月8日，安进公司与协和麒麟株式会社公布了ROCKET III期临床试验项目的最新结果。该项目正在评估rocatinlimab用于治疗中重度特应性皮炎的疗效。IGNITE研究评估了rocatinlimab的两种剂量强度，达到了共同主要终点和所有关键次要终点，两种剂量组相较于安慰剂组均显示出统计学显著差异。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517442358","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517442358?lang=zh_cn&edition=full","pubTime":"2025-03-08 22:00","pubTimestamp":1741442455,"startTime":"0","endTime":"0","summary":"3月8日，安进公司与协和麒麟株式会社公布了ROCKET III期临床试验项目的最新结果。该项目正在评估rocatinlimab用于治疗中重度特应性皮炎的疗效。IGNITE研究评估了rocatinlimab的两种剂量强度，达到了共同主要终点和所有关键次要终点，两种剂量组相较于安慰剂组均显示出统计学显著差异。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08220048611823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4566","SG9999001440.SGD","LU0122379950.USD","LU1571399168.USD","BK4581","BK4534","LU0289739699.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B2B36J28.USD","03347","LU1983299246.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","BK1141","BK1576","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4588","BK4599","BK4134","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU2242652126.USD","BK4533","III","IE00BFTCPJ56.SGD","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","BK1583","LU0868494617.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2517448458","title":"医药生物行业专题：海外制药企业2024Q4&全年业绩回顾","url":"https://stock-news.laohu8.com/highlight/detail?id=2517448458","media":"国信证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517448458?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:14","pubTimestamp":1741349673,"startTime":"0","endTime":"0","summary":"代谢：诺和诺德Ozempic+Wegovy+Rybelsus 2024年合计销售~293亿美元，礼来Mounjaro+Zepbound合计销售~165亿美元；美国降糖相关GLP-1总处方量增速15%+，2025年初减重GLP-1周度处方量较2024年初增长 ~3x。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307201454989fd3c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307201454989fd3c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","ABBV","LU0122379950.USD","LU1718418525.SGD","LU0820561909.HKD","LU0795875169.SGD","LU1934455194.USD","LU0256863902.USD","LU0170899867.USD","LU2237443978.SGD","LU1551013342.USD","BK4139","LU2237443549.SGD","LU0949170772.SGD","LU0211328371.USD","LU1267930573.SGD","IE00B42XCP33.USD","LU1244550494.USD","LU1732799900.SGD","IE0004445239.USD","LU2237443465.HKD","LU1585245621.USD","LU1267930490.SGD","LU0985320562.USD","LLY","IE0002141913.USD","LU0256863811.USD","LU1291159041.SGD","LU2237443622.USD","LU1496350502.SGD","LU2468319806.SGD","LU0965509101.SGD","BK4559","LU1430594728.SGD","AZN","LU0912757837.SGD","LU1989772923.USD","LU1037948897.HKD","LU0553294199.USD","LU0965509283.SGD","LU0310799852.SGD","LU1003077747.HKD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU1244550221.USD","IE00BDGV0183.EUR","LU1037948541.HKD","LU0738911758.USD","LU1732800096.USD","AMGN","IE00B4R5TH58.HKD","LU2237443382.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2517175213","title":"安进(AMGN.US)AMG 133启动减重III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2517175213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517175213?lang=zh_cn&edition=full","pubTime":"2025-03-07 15:29","pubTimestamp":1741332593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133的两项III期临床试验，标志着AMG 133进入III期开发阶段。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽偶联药物，由靶向葡萄糖依赖性促胰岛素释放多肽受体的全人源单抗偶联两个GLP-1类似物而成，通过抑制GIPR并激活GLP-1受体来发挥减少食物摄入和调节代谢进而减轻体重和降低血糖的作用。AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4566","SG9999001440.SGD","LU0122379950.USD","LU1571399168.USD","BK4581","BK4534","BK4505","LU0289739699.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","BK4135","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4588","BK4599","AMG","BK4134","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU2242652126.USD","BK4533","III","IE00BFTCPJ56.SGD","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","LU0868494617.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2517276311","title":"首个肿瘤mRNA疫苗有望在2027年推出；安进减肥药启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2517276311","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517276311?lang=zh_cn&edition=full","pubTime":"2025-03-07 14:09","pubTimestamp":1741327740,"startTime":"0","endTime":"0","summary":"mRNA肿瘤疫苗的重磅节点，可能近了。安进继续押注减肥药。/ 05 / 海外药闻1）首个肿瘤mRNA疫苗有望在2027年推出3月5日，Moderna在投资者会议上表示，该公司有望于2027年推出首个mRNA肿瘤疫苗V940。2）安进AMG 133启动减重III期临床3月5日，据全球临床试验收录网站clinicaltrials，安进启动了AMG 133的两项减重III期临床试验，标志着AMG 133进入III期开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307141635989f7805&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307141635989f7805&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","SG9999001440.SGD","LU0122379950.USD","LU1571399168.USD","BK4581","BK4534","LU0289739699.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4588","BK4599","BK4134","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU2242652126.USD","BK4533","III","IE00BFTCPJ56.SGD","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","LU0868494617.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2517013632","title":"每月1针！安进AMG 133启动减重III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2517013632","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517013632?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:50","pubTimestamp":1741251040,"startTime":"0","endTime":"0","summary":"3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133的两项III期临床试验，标志着AMG 133进入III期开发阶段。MARITIME-2是一项随机、双盲、安慰剂对照临床试验，旨在评估AMG 133在伴2型糖尿病的肥胖或超重成人患者中的有效性、安全性和耐受性。AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","SG9999001440.SGD","LU0122379950.USD","LU1571399168.USD","BK4581","BK4534","BK4505","LU0289739699.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","BK4135","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4588","BK4599","AMG","BK4134","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU2242652126.USD","BK4533","III","IE00BFTCPJ56.SGD","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","LU0868494617.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"1198097071","title":"美银证券分析师：强生等五支生物制药股可能会蓄势突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1198097071","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198097071?lang=zh_cn&edition=full","pubTime":"2025-03-06 11:29","pubTimestamp":1741231784,"startTime":"0","endTime":"0","summary":"美国银行证券分析师Tim Anderson认为，一批生物制药领域的\"大块头\"或迎来机遇。截至周二，这五支股票在该机构覆盖的大型生物制药股中涨幅居前。分析师指出，公司收入稳定性强、每股收益长期增长，且市盈率处于行业平均水平。尽管本周启动两项后期试验，Anderson认为该药\"可能继续令人失望\"，但若商业表现超预期仍有上涨空间。分析师指出其估值溢价可能被市场忽视，在行业动荡期被视为\"避风港\"，且医疗科技业务独具优势。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"美银证券分析师：强生等五支生物制药股可能会蓄势突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","ABBV","JNJ","AMGN","LLY"],"gpt_icon":1},{"id":"2517401509","title":"B of A Securities：维持Amgen(AMGN.US)评级，由低于大市调整至低于大市评级, 目标价由275.00美元调整至294.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517401509","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517401509?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:12","pubTimestamp":1741198339,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Amgen(AMGN.US)评级，由低于大市调整至低于大市评级, 目标价由275.00美元调整至294.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06021248550885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AMGN"],"gpt_icon":0},{"id":"2514350322","title":"百济神州，正在走安进曾经的路","url":"https://stock-news.laohu8.com/highlight/detail?id=2514350322","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514350322?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:28","pubTimestamp":1740698880,"startTime":"0","endTime":"0","summary":"随着百济神州2024年财报的披露，其再次向市场深化了“创新药一哥”的定位。无论是市值规模，还是产品成熟度，百济神州显然与安进都不是一个等级的对手，简单静态对比并不能得出什么有效结论。如果以此视角推测，虽然不能说百济神州估值过高，但也应警惕如当年安进估值回落盘整的风险。如果说百济神州正在走安进曾经的路，那么长达十二年的潜在瓶颈期才是最考验投资者认知的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022808161998958181&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022808161998958181&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","LU0058720904.USD","IE00B4R5TH58.HKD","LU0868494617.USD","LU0109394709.USD","LU0289739699.SGD","BK4588","LU1983299246.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","LU1571399168.USD","BK4581","ONC","IE00BFTCPJ56.SGD","LU2242646821.SGD","BK4534","SG9999001440.SGD","AMGN","06160","LU1061106388.HKD","BK4566","BK4599","LU0889565916.HKD","LU2242652126.USD","BK4139","BK4533","LU0122379950.USD","IE0009355771.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"2514286547","title":"安进盘中异动 股价大跌3.00%报306.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514286547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514286547?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:56","pubTimestamp":1740592595,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时56分，安进股票出现波动，股价大幅跳水3.00%。截至发稿，该股报306.15美元/股，成交量127.737万股，换手率0.24%，振幅2.34%。最近的财报数据显示，该股实现营业收入332.32亿美元，净利润40.90亿美元，每股收益7.62美元，毛利213.33亿美元，市盈率40.51倍。安进股票所在的制药行业中，整体跌幅为0.22%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227015635963175b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227015635963175b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","LU0058720904.USD","IE00B4R5TH58.HKD","LU0868494617.USD","LU0109394709.USD","LU0289739699.SGD","BK4588","LU1983299246.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","LU1571399168.USD","BK4581","IE00BFTCPJ56.SGD","LU2242646821.SGD","BK4534","SG9999001440.SGD","AMGN","LU1061106388.HKD","BK4566","BK4599","LU0889565916.HKD","LU2242652126.USD","BK4139","BK4533","LU0122379950.USD","IE0009355771.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"2513272743","title":"生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272743","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513272743?lang=zh_cn&edition=full","pubTime":"2025-02-24 18:22","pubTimestamp":1740392540,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物科技巨头安进公司首席执行官罗伯特·布拉德韦周一在印度海得拉巴大型基地落成典礼上表示，公司今年将向其位于印度南部的这一新建成的技术中心投资大约2亿美元，并计划未来追加更大规模投资。安进将在2025年向该中心投入首期2亿美元资金，并计划未来数年追加重大投资。本周海得拉巴还将举办BioAsia生物科技大会，安进、礼来、诺华等全球跨国药企高管及多家印度制药巨头高管将发表演讲。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253481.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","BK4139","IE00BJT1NW94.SGD","LU1023059063.AUD","LU1571399168.USD","LU1061106388.HKD","BK1191","LU0289739699.SGD","BK4581","LU2242646821.SGD","LU0109394709.USD","BK4566","BK4534","BK4585","AMGN","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU2242652126.USD","IE0009355771.USD","LU1057294990.SGD","LU0889565916.HKD","BK4599","LU0122379950.USD","LU1983299246.USD","LU0868494617.USD","BK1574","IE0002141913.USD","LU2112291526.USD","LU0320765992.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","BK4588"],"gpt_icon":0},{"id":"2513715981","title":"安进承诺今年将在印度新技术中心投资约2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513715981","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513715981?lang=zh_cn&edition=full","pubTime":"2025-02-24 14:57","pubTimestamp":1740380227,"startTime":"0","endTime":"0","summary":"格隆汇2月24日｜据路透，美国制药商安进公司首席执行官Robert Bradway周一表示，该公司今年将在其位于印度南部的新技术中心投资约2亿美元，并计划在未来几年进一步投资。安进公司去年宣布计划在印度开设一个“技术与创新”中心，重点是增加人工智能和数据科学的使用以支持新药的开发。据悉，位于印度特伦甘纳邦首府海得拉巴的工厂到今年年底预计将拥有约2000名员工，目前已有约300名员工在那里工作。本周，该市还将主办BioAsia会议，安进、礼来和诺华等全球制药公司的高管以及几家印度制药巨头将在会上发言。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224145719962e1a65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224145719962e1a65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFTCPJ56.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU1023059063.AUD","LU1571399168.USD","LU1061106388.HKD","IE00B4R5TH58.HKD","BK4581","BK4139","BK4585","LU0868494617.USD","SG9999001440.SGD","LU0109394709.USD","LU0320765992.SGD","LU1983299246.USD","BK4588","BK4599","LU0122379950.USD","BK4534","IE00BJJMRZ35.SGD","IE0002141913.USD","LU2112291526.USD","BK4533","LU0289739699.SGD","IE00B2B36J28.USD","BK4566","LU2242652126.USD","LU0058720904.USD","LU0889565916.HKD","IE0009355771.USD","AMGN"],"gpt_icon":0},{"id":"2513798267","title":"华泰证券：国产GLP-1产品有望抢占全球市场份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2513798267","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513798267?lang=zh_cn&edition=full","pubTime":"2025-02-24 10:02","pubTimestamp":1740362546,"startTime":"0","endTime":"0","summary":"2月24日，华泰证券发布医药健康行业深度研究报告称，GLP-1已展现较大的市场潜力，而目前海外MNC仅诺和诺德和礼来两巨头销售领先，但尚未形成完整产品矩阵，其他MNC产品仍处于临床阶段，竞争格局尚未定型，产品空缺较大。而2023年至今国产GLP-1出海交易频现，华泰证券认为国产GLP-1产品竞争力不输海外，其中GLP-1口服小分子、GLP-1/GIP、GLP-1/GIP/GCGR、GLP-1/GCGR/FGF21、ActRII等靶点不乏临床进展领先的优质资产，未来有望借助BD进军全球市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224100328962dd889&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224100328962dd889&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLP","LU0868494617.USD","BK4585","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","LU1571399168.USD","LU2112291526.USD","LU1983299246.USD","IE00B4R5TH58.HKD","LU0058720904.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4533","LU1023059063.AUD","LLY","IE0002141913.USD","LU0122379950.USD","IE00B2B36J28.USD","LU0289739699.SGD","NVO","LU2242646821.SGD","SG9999001440.SGD","BK4599","BK4588","IE00BFTCPJ56.SGD","BK4590","AMGN","BK4581","LU2242652126.USD","IE00BJJMRZ35.SGD","BK4139","BK4534","IE0009355771.USD","BK4144","LU1057294990.SGD","BK4566"],"gpt_icon":0},{"id":"2513292688","title":"安进涨0.69% 股价突破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2513292688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513292688?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:48","pubTimestamp":1740152906,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时48分，安进股票出现波动，股价大幅上涨0.69%。截至发稿，该股报300.00美元/股，成交量36.4454万股，换手率0.07%，振幅0.92%。安进股票所在的制药行业中，整体涨幅为1.19%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。该信息摘要如下：2025年2月12日，美国特拉华州联邦法院作出裁定，安进成为和铂医药专利维权案中的新被告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221234826962b8c9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221234826962b8c9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","SG9999001440.SGD","LU0320765992.SGD","LU0289739699.SGD","BK4581","BK4599","LU1057294990.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU1061106388.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","LU1983299246.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","AMGN","LU0058720904.USD","LU2112291526.USD","IE00BJT1NW94.SGD","LU2242652126.USD","LU0868494617.USD","BK4588","BK4566","LU0889565916.HKD","LU1571399168.USD","LU0122379950.USD","BK4534","IE0002141913.USD","BK4139","BK4585"],"gpt_icon":0},{"id":"2512640481","title":"中银证券安进债券A连续7个交易日下跌，区间累计跌幅2.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512640481","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512640481?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:09","pubTimestamp":1739894978,"startTime":"0","endTime":"0","summary":"2月18日，中银证券安进债券A下跌0.09%，最新净值1.06元，连续7个交易日下跌，区间累计跌幅2.52%。据了解，中银证券安进债券A成立于2016年12月，基金规模345.91亿元，成立来累计收益率33.55%。从持有人结构来看，截至2024年上半年，中银证券安进债券A的基金机构持有319.43亿份，占总份额的100.00%，个人投资者持有0.01亿份，占总份额的0.00%。截止2024年12月31日，中银证券安进债券A前五持仓占比合计40.60%，分别为：23国开、23国开、22国开、22国开、22国开。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/19000948241701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4533","SG9999001440.SGD","LU0320765992.SGD","LU0289739699.SGD","BK4581","BK4599","LU1057294990.SGD","IE00BFTCPJ56.SGD","601696","IE0009355771.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU1061106388.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","LU1983299246.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","AMGN","LU0058720904.USD","LU2112291526.USD","IE00BJT1NW94.SGD","LU2242652126.USD","LU0868494617.USD","BK4588","BK4566","LU0889565916.HKD","LU1571399168.USD","LU0122379950.USD","BK4534","BK0276","IE0002141913.USD","BK4139","BK4585"],"gpt_icon":0},{"id":"2512909418","title":"从被狙击到反击，中国Biotech正面硬刚跨国药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2512909418","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512909418?lang=zh_cn&edition=full","pubTime":"2025-02-18 10:20","pubTimestamp":1739845214,"startTime":"0","endTime":"0","summary":"和铂医药2021年将Teneobio告上法庭，称对方侵犯了公司专利。像这样由一家中国Biotech主动进攻跨国巨头，维护自己专利的案例在过去并不常见。最终，法院驳回了安进的要求。在此前的媒体采访中，和铂生物首席科学家戎一平博士就提到，“中国Biotech也需要注意专利保护，目前从国内企业对专利保护的考虑还不够充分，一旦出海，尤其是在商业化阶段，就会遭到国际知识产权保护的强烈冲击。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218102051abd2f0ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218102051abd2f0ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMGN","BK1574","06978","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2511612606","title":"安进下跌1.23%，报290.98美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2511612606","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511612606?lang=zh_cn&edition=full","pubTime":"2025-02-15 04:41","pubTimestamp":1739565709,"startTime":"0","endTime":"0","summary":"2月15日，安进(AMGN)盘中下跌1.23%，截至04:41，报290.98美元/股，成交3.86亿美元。财务数据显示，截至2024年12月31日，安进收入总额334.24亿美元，同比增长18.57%；归母净利润40.9亿美元，同比减少39.11%。大事提醒：2月10日，安进获Piper Sandler上调目标价至329美元，最新评级Overweight。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/15044148179716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","IE0002141913.USD","LU1057294990.SGD","BK4599","BK4566","LU0889565916.HKD","BK4581","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4534","LU0868494617.USD","LU1571399168.USD","BK4533","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4585","SG9999001440.SGD","LU2242646821.SGD","IE0009355771.USD","LU2242652126.USD","LU1983299246.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU0109394709.USD","BK4588","LU0320765992.SGD","LU2112291526.USD","LU1061106388.HKD","AMGN"],"gpt_icon":0},{"id":"2509728091","title":"安进下跌1.21%，报294.183美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509728091","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509728091?lang=zh_cn&edition=full","pubTime":"2025-02-07 23:55","pubTimestamp":1738943704,"startTime":"0","endTime":"0","summary":"2月7日，安进(AMGN)盘中下跌1.21%，截至23:55，报294.183美元/股，成交1.62亿美元。财务数据显示，截至2024年12月31日，安进收入总额334.24亿美元，同比增长18.57%；归母净利润40.9亿美元，同比减少39.11%。大事提醒：2月6日，安进获美国银行上调目标价至275美元，最新评级Underperform。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/07235548031228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4585","BK4534","BK4139","LU1057294990.SGD","IE0002141913.USD","LU0058720904.USD","BK4581","LU0868494617.USD","LU1061106388.HKD","LU1571399168.USD","LU1983299246.USD","LU0109394709.USD","LU2112291526.USD","BK4533","IE0009355771.USD","BK4599","AMGN","LU0122379950.USD","LU2242646821.SGD","LU2242652126.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4566","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","SG9999001440.SGD","BK4588"],"gpt_icon":0},{"id":"2509771722","title":"一药企宣布，暂停开发减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2509771722","media":"康可药研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509771722?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:30","pubTimestamp":1738938642,"startTime":"0","endTime":"0","summary":"安进宣布暂停开发减肥药2月4日，安进发布消息，暂停开发减肥药。与此同时，安进减肥药MariTide隐藏骨密度数据，引发股市震荡，市值蒸发近120亿美元。但在2月4日，安进选择了暂停开发减肥药，同时，安进公布了最新的业绩，其全年总收入达到334亿美元，同比增长19%。对于安进而言，在MariTide减肥效果不达预期下，暂停相关减肥药的开发似乎是不二选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208020735abc658bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208020735abc658bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","IE00BFTCPJ56.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","BK4581","LU2112291526.USD","BK4139","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4599","IE00B4R5TH58.HKD","BK4585","LU0320765992.SGD","LU0109394709.USD","IE0002141913.USD","LU0289739699.SGD","LU1057294990.SGD","SG9999001440.SGD","BK4588","LU1023059063.AUD","BK4533","LU1571399168.USD","LU2242652126.USD","BK4566","LU1061106388.HKD","LU0058720904.USD","LU1983299246.USD","LU0889565916.HKD","LU2242646821.SGD","AMGN","LU0868494617.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.0918},{"period":"1month","weight":-0.1175},{"period":"3month","weight":0.0731},{"period":"6month","weight":-0.143},{"period":"1year","weight":0.0561},{"period":"ytd","weight":0.0797}],"compareEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":-0.0564},{"period":"3month","weight":-0.0963},{"period":"6month","weight":-0.0949},{"period":"1year","weight":0.0203},{"period":"ytd","weight":-0.1049}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amgen Inc是一家生物技术公司。该公司从事发现、开发、生产和提供治疗最棘手疾病的药物。该公司专注于医疗需求尚未得到满足的领域，并利用专业知识努力寻求改善人们生活的解决方案。该公司在人类治疗领域开展业务。该公司的营销产品组合包括EPOGEN（阿法依泊汀）、Aranesp（阿法达贝泊汀）、Parsabiv（etelcalcetide）、Neulasta（培非格司亭）；KANJINTI（曲妥珠单抗）、Otezla、BLINCYTO（blinatumomab）、ACTIMMUNE（干扰素γ-1b）、Neulasta（培非格司亭）、Sensipar/Mimpara（西那卡塞）、Prolia（地舒单抗）、ENBREL、QUINSAIR（左氧氟沙星）、Repatha（依洛尤单抗）等。该公司在美国和加拿大销售肿瘤坏死因子阻断剂ENBREL。该公司在全球许多国家销售抑制磷酸二酯酶4的小分子药物Otezla。该公司在全球许多国家销售前蛋白转化酶枯草溶菌素/kexin 9型 (PCSK9) 抑制剂Repatha。","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.034093},{"month":2,"riseRate":0.47619,"avgChangeRate":-0.001155},{"month":3,"riseRate":0.52381,"avgChangeRate":0.019224},{"month":4,"riseRate":0.452381,"avgChangeRate":-0.003579},{"month":5,"riseRate":0.536585,"avgChangeRate":0.024998},{"month":6,"riseRate":0.512195,"avgChangeRate":0.004729},{"month":7,"riseRate":0.761905,"avgChangeRate":0.052458},{"month":8,"riseRate":0.619048,"avgChangeRate":0.005154},{"month":9,"riseRate":0.52381,"avgChangeRate":0.002807},{"month":10,"riseRate":0.52381,"avgChangeRate":0.020682},{"month":11,"riseRate":0.619048,"avgChangeRate":0.019128},{"month":12,"riseRate":0.642857,"avgChangeRate":0.047779}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}